Drug Research
Roche’s Tecentriq shows positive results for lung-cancer treatment
Roche Holding AG (ROG.EB) said that a phase 3 IMpower150 study showed an improvement in the treatment of advanced lung cancer with the use of Tecentriq. The study showed that patients with advanced lung cancer live...
Drug Research
Johnson & Johnson Human Performance Institute Invests $18 Million for future of Lake Nona Medical City
The Johnson & Johnson Human Performance Institute today announced it is expanding its footprint in the Lake Nona community in Orlando, Florida with the construction of its new global headquarters. The $18 million state-of-the-art campus, located...
Drug Research
ADC Bio developing downstream bioconjugation process
ADC Biotechnology (ADC Bio) announces that it is developing a revolutionary, ‘downstream bioconjugation’ method that will present a new paradigm in Antibody Drug Conjugate (ADC) development and manufacturing. In contrast to the existing approaches – which...
Drug Research
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration...
Drug Research
Inovio, Parker Institute for Cancer Immunotherapy enter clinical collaboration to evaluate new cancer immunotherapy combinations
Inovio Pharmaceuticals, Inc. and the Parker Institute for Cancer Immunotherapy have entered into a clinical collaboration agreement that provides for Inovio and the Parker Institute to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology. ...
Drug Research
STORM Therapeutics Extends Series A Round to Include New Investor Taiho Ventures
STORM Therapeutics, the leading drug discovery company focused on small molecule therapies modulating RNA modifying enzymes, announced that it has raised an additional GBP4 million of funding from Taiho Ventures, LLC the strategic corporate venture capital arm of Taiho...
Drug Research
Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, announced that AstraZeneca will use the Company’s myChoice® HRD Plus in an exploratory analysis to identify women with advanced ovarian cancer who may benefit from maintenance treatment...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
